{"id":742914,"date":"2023-03-27T16:21:25","date_gmt":"2023-03-27T20:21:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/"},"modified":"2023-03-27T16:21:25","modified_gmt":"2023-03-27T20:21:25","slug":"nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/","title":{"rendered":"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">PARIS and CAMBRIDGE, Mass., March  27, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I-lPWcQyqHxOVCiVEkjPiEZ9F6cdHpCp3j6zzmJXu05e3-isHNuJBE0ZOvagIv1-y1dhQGAkSkLKQJ2Syoe1rQ==\" rel=\"nofollow noopener\" target=\"_blank\">NANOBIOTIX<\/a> (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018<strong>Company<\/strong>\u2019\u2019), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023.<\/p>\n<p align=\"justify\">The company will announce its full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures.<\/p>\n<p align=\"justify\">\n        <strong>About NANOBIOTIX: <\/strong><br \/>\n        <br \/>Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company\u2019s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.<\/p>\n<p align=\"justify\">Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.<\/p>\n<p align=\"justify\">Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. The company&#8217;s resources are primarily devoted to the development of its lead product candidate\u2013NBTXR3\u2014which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify<sup>\u00ae<\/sup>.<\/p>\n<p align=\"justify\">For more information about Nanobiotix, visit us at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6PC0JjrwVEl-iy-Pal12UTnQgMuefDpuSpwpSf7p2GQrmBobT5jHA6xnC8bYuIWAjMrn3yS56NG0hBfojPqMBHbseK3vUUC5iOmtMlyJKVU=\" rel=\"nofollow noopener\" target=\"_blank\">www.nanobiotix.com<\/a> or follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PJAVeO4r7GDiOkZtcuOpDAo8mgPh7Loa8wxE3sHj3TcDfxBifGQswum0dpnbHNSiO0wz7vh41PH95phQybGFm9ScVK3Y-TbGGtU23J78rfA=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iToDyDCgyh4vVI2KL4D32XkTKrcQVOcsBmUhFgSA3S43JORhdmhDnlHxJ-s_jdKfLerhVnIwihTJNRY8HbFc5A==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Contacts<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>Nanobiotix<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;border-bottom: solid black 1pt;vertical-align: bottom\">\n            <strong>Communications Department<\/strong><br \/>\n            <br \/>\n            <em>Brandon Owens<\/em><br \/>\n            <br \/>\n            <em>VP, Communications<\/em><br \/>\n            <br \/>+1 (617) 852-4835<br \/><a href=\"mailto:contact@nanobiotix.com\" rel=\"nofollow noopener\" target=\"_blank\">contact@nanobiotix.com<\/a><\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;border-top: solid black 1pt;vertical-align: bottom\">\n            <strong>Investor Relations Department<\/strong><br \/>\n            <br \/>\n            <em>Kate McNeil<\/em><br \/>\n            <br \/>\n            <em>SVP, Investor Relations<\/em><br \/>\n            <br \/>+1 (609) 678-7388<br \/><a href=\"mailto:investors@nanobiotix.com\" rel=\"nofollow noopener\" target=\"_blank\">investors@nanobiotix.com<\/a><\/td>\n<\/tr>\n<tr>\n<td colspan=\"2\" style=\"border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>Media Relations<\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;vertical-align: bottom\">FR \u2013\u00a0<strong>Ulysse Communication<\/strong><br \/>Pierre-Louis Germain<br \/>+ 33 (0) 6 64 79 97 51<br \/><a href=\"mailto:plgermain@ulysse-communication.com\" rel=\"nofollow noopener\" target=\"_blank\">plgermain@ulysse-communication.com<\/a><\/td>\n<td style=\"border-top: solid black 1pt;vertical-align: bottom\">Global \u2013\u00a0<strong>LifeSci Advisors<\/strong><br \/>Ligia Vela-Reid<br \/>+44 (0) 7413825310<br \/><a href=\"mailto:Lvela-reid@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">Lvela-reid@lifesciadvisors.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong><br \/>\n          <br \/>Attachment<\/strong><br \/>\n        \n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li style=\"text-align:justify\">\n          <a href=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/88e134c1-e733-4b92-b5f1-db97be4a526c\" rel=\"nofollow noopener\" target=\"_blank\">2023-03-27 &#8212; NBTX &#8212; Postponing FY22 Financial Results &#8212; FINAL<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmYyZWNjOWQtMzhlZi00NGY2LWE3YjQtYjUzZWM3MDBmY2UxLTEwMTExNjI=\/tiny\/Nanobiotix-S-A-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) &#8212; NANOBIOTIX (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023. The company will announce its full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures. About NANOBIOTIX: Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-742914","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) &#8212; NANOBIOTIX (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023. The company will announce its full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures. About NANOBIOTIX: Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions &hellip; Continue reading &quot;Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-27T20:21:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call\",\"datePublished\":\"2023-03-27T20:21:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/\"},\"wordCount\":347,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/\",\"name\":\"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=\",\"datePublished\":\"2023-03-27T20:21:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/","og_locale":"en_US","og_type":"article","og_title":"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call - Market Newsdesk","og_description":"PARIS and CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) &#8212; NANOBIOTIX (Euronext: NANO \u2013\u2013 NASDAQ: NBTX \u2013 the \u2018\u2018Company\u2019\u2019), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023. The company will announce its full year 2022 financial results and conference call schedule in a future press release to allow additional time to complete its year-end closing procedures. About NANOBIOTIX: Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions &hellip; Continue reading \"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-27T20:21:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call","datePublished":"2023-03-27T20:21:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/"},"wordCount":347,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/","name":"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=","datePublished":"2023-03-27T20:21:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc5NjMyOCM1NDk0Mjg0IzEwMTExNjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanobiotix-to-postpone-full-year-2022-financial-results-and-conference-call\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=742914"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/742914\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=742914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=742914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=742914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}